Thyrocare Technologies (NSE:THYROCARE) Tax Expense: ₹500 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:THYROCARE Thyrocare Technologies Ltd NSE:THYROCARE
88 GF Score
Price ₹557.95
GF Value ₹397.30
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Thyrocare Technologies Tax Expense?

Thyrocare Technologies NSE:THYROCARE -0.87% 88 Tax Expense is ₹500 Mil as of Mar. 2026. GuruFocus rates NSE:THYROCARE with a GF Score™ of 88/100 and a GF Value™ of ₹397.30 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Thyrocare Technologies's tax expense for the months ended in Mar. 2026 was ₹157 Mil. Its tax expense for the trailing twelve months (TTM) ended in Mar. 2026 was ₹500 Mil.


Thyrocare Technologies  (NSE:THYROCARE) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Thyrocare Technologies Tax Expense Related Terms


Thyrocare Technologies Tax Expense Historical Data

* Premium members only.

The historical data trend for Thyrocare Technologies's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thyrocare Technologies Tax Expense Chart

Thyrocare Technologies Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 515.80 242.30 264.90 546.90 500.30

Thyrocare Technologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 256.20 121.90 147.70 73.40 157.30
NSE:THYROCARE
88GF Score
Thyrocare Technologies Ltd NSE:THYROCARE
Tax Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Thyrocare Technologies Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹500 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Expense →
What does a Tax Expense of ₹500 Mil mean?
Thyrocare Technologies (NSE:THYROCARE) has a Tax Expense of ₹500 Mil as of Mar. 2026. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Thyrocare Technologies and its competitors.
Is Thyrocare Technologies' Tax Expense too high?
Thyrocare Technologies' current Tax Expense is ₹500 Mil. Overall, Thyrocare Technologies has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Thyrocare Technologies' Tax Expense compare to TMO and DHR?
Thyrocare Technologies' Tax Expense of ₹500 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Expense for a Medical Diagnostics & Research company?
A good Tax Expense depends on the Medical Diagnostics & Research industry context. However, Tax Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Expense mean?
A high Tax Expense can signal that a stock is expensive relative to its fundamentals. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Thyrocare Technologies and its competitors. Thyrocare Technologies's current Tax Expense is ₹500 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thyrocare Technologies stock overvalued right now?
Based on GuruFocus' analysis, Thyrocare Technologies (NSE:THYROCARE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹397.30, compared to a current price of ₹557.95 — trading 40.4% above its estimated fair value. The current Tax Expense is ₹500 Mil. Thyrocare Technologies' overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Expense calculated?
Tax Expense is calculated from a company's financial statements. For Thyrocare Technologies (NSE:THYROCARE), the current Tax Expense is ₹500 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Thyrocare Technologies (NSE:THYROCARE) Overvalued in 2026?

Based on GuruFocus' analysis, Thyrocare Technologies stock appears to be overvalued. The current stock price of ₹557.95 is trading 40.4% above its estimated GF Value™ of ₹397.30. GuruFocus considers Thyrocare Technologies to be Significantly Overvalued.

Key valuation signals for NSE:THYROCARE:

  • Tax Expense: ₹500 Mil
  • GF Value™: ₹397.30 vs. price of ₹557.95 (40.4% above fair value)
  • GF Score™: 88/100 with 5 warning signs

No single metric tells the full story. See the NSE:THYROCARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Thyrocare Technologies Business Description

Other Exchanges 539871:India
Address D-37/3, TTC Industrial Area, MIDC, Turbhe, Opposite Sandoz, Navi Mumbai, MH, IND, 400703
Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Others: Sale of testing equipment and consumables. The Diagnostic Testing Services segment provides Diagnostic and testing services, selling of consumables used for the collection and promotion of the pathology segment. The company majorly earns the majority of its revenue from the Diagnostic Testing Services segment. The Imaging Services segment operates Diagnostic and imaging services, selling of radio-pharmaceuticals, and selling of consumables for reporting. The Other business segment is engaged in the selling of glucometers and glucostrips under the brand name Sugarscan. The company earns the vast majority of its revenue in India.
88GF Score

Get the complete analysis for NSE:THYROCARE

Tax Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹557.95
Price
₹397.30
GF Value